A Phase 2b Diabetic Kidney Disease Study
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 609 participants.
Also called NCT04170543
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 609 participants
- Sponsor
- Registry
-
NCT04170543
-
- Other papers using this trial's data
- Inhibition of IL-33 in Diabetic Kidney Disease: A Randomized, Placebo-Controlled Phase 2b Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Canada, Chile, Japan, Peru, South Korea
- Registry status
- Completed
Technical summary
Registry record NCT04170543. Randomized; quadruple masking; primary purpose treatment. Start 2019-11-18 (actual); primary completion 2023-05-16 (actual). Results posted on 2024-07-10.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 2b Diabetic Kidney Disease Study
- Condition
- Diabetic Kidney Disease
- Intervention (Drug)
- MEDI3506
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Dapagliflozin
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct04170543- Content hash
f2361da776f9c97060ff37f131eec66ca978eee47f7383fe44f6e35676b8c8ec